Novo Nordisk’s Wegovy wins EU backing for reducing heart risks

Home » Blog » Novo Nordisk’s Wegovy wins EU backing for reducing heart risks

July 27, 2024July 27, 2024

Novo Nordisk’s Wegovy has received backing from the EU’s medical regulator to expand the weight loss drug’s use to reducing the rise of serious heart events.

Previous PostEurostar cancels quarter of train services ahead of Olympics after arson attacks on French railwayNext PostWarner Bros. Discovery sues NBA to secure media rights awarded to Amazon

Latest Articles

Bitcoin vs. gold: State Street worries the crypto rally’s allure is distracting precious metal investors
Data centers powering artificial intelligence could use more electricity than entire cities
Germany’s Merkel laments influence of big business on Trump
Welcome to the mullet market: Steady benchmarks in the front, crypto party in the back
How tech bros bought ‘America’s most pro-crypto Congress ever’
COP29 clinches $300 billion climate finance deal
How Elon Musk’s plan to slash government agencies and regulation may benefit his empire
Why X’s new terms of service are driving some users to leave Elon Musk’s platform
The Pentagon’s battle inside the U.S. for control of a new Cyber Force
Top 10 S&P 500 stock winners since Election Day

Advertising

GTR provides global news on topics ranging from world markets, investing opportunities, industry analysis and so much more.

News

Finance
Investments
Technology

Countries

Worldwide
Africa
Asia
Australia
Canada
Europe
United States

Official

Magazines
Videos
About Us
Contact Us
Privacy
Terms & Conditions